We performed a 5-question survey of 18 medical oncologists in the US to gauge current prescribing practices for ovarian cancer treatments and diagnostics and gauge interest in new drug candidates for the treatment of ovarian cancer.
Drugs and drug candidates discussed: Avastin,vintafolide, olaparib
How many patients with ovarian, fallopian tube, or primary peritoneal cancer are you currently treating?
What percentage of your ovarian cancer patients received these treatments in the following settings in the last three months? [free numerical response for each choice]
Vintafolide is a folic acid-vinblastine conjugate. In a trial, patients with folate receptor-positive, Pt-resistant ovarian cancer receiving vintafolide+Doxil had improved PFS (5.5 months vs 2.7 months for Doxil only); safety profile was similar to Doxil alone. If vintafolide is approved, how many of your Pt-resistant ovarian cancer patients will receive vintafolide under these conditions:
What percentage of your ovarian cancer patients receive BRCA mutation testing of any kind?
Olaparib is a PARP inhibitor being tested as a maintenance therapy for relapsed, Pt-sensitive, BRCA-mutated ovarian cancer patients in CR or PR (table below). Patients receive olaparib PO QD until progression or unacceptable toxicity. If olaparib is approved at the end of 2014, how will you prescribe it at the following times:
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.